Designer benzodiazepines: an update

References

• Sellers EM. Deconstructing designer drugs. Clin Pharmacol Ther. 2017;101(2):167–169.
   PubMed Web of Science ®Google Scholar
• Baumeister D, Tojo LM, Tracy DK. Legal highs: staying on top of the flood of novel psychoactive substances. Ther Adv Psychopharmacol. 2015;5(2):97–132.
   PubMed Web of Science ®Google Scholar
• Moosmann B, Auwärter V. Designer benzodiazepines: another class of new psychoactive substances. Handb Exp Pharmacol. 2018;252:383–410.
   PubMedGoogle Scholar
• Greenblatt HK, Greenblatt DJ. Designer benzodiazepines: a review of published data and public health significance. Clin Pharmacol Drug Dev. 2019;8(3):266–269.
   PubMed Web of Science ®Google Scholar
• Moustafa RE, Tarbah F, Saeed HS, et al. Designer benzodiazepines versus prescription benzodiazepines: can structural relation predict the next step? Crit Rev Toxicol. 2021;51(3):249–263.
   PubMed Web of Science ®Google Scholar
• Zawilska JB, Wojcieszak J. An expanding world of new psychoactive substances – designer benzodiazepines. Neurotoxicology. 2019;73:8–16.
   PubMed Web of Science ®Google Scholar
• Manchester KR, Lomas EC, Waters L, et al. The emergence of new psychoactive substance (NPS) benzodiazepines: a review. Drug Test Anal. 2018;10(2):392–393.
   PubMed Web of Science ®Google Scholar
• Edinoff AN, Nix CA, Odisho AS, et al. Novel designer benzodiazepines: comprehensive review of evolving clinical and adverse effects. Neurol Int. 2022;14(3):648–663.
   PubMed Web of Science ®Google Scholar
• Auwärter V, de Morais J, Gallegos A, et al. New benzodiazepines in Europe – a review. European Monitoring Center for Drugs and Drug Addiction. Luxembourg: Publications Office of the European Union; 2021.
   Google Scholar
• Brunetti P, Giorgetti R, Tagliabracci A, et al. Designer benzodiazepines: a review of toxicology and public health risks. Pharmaceuticals (Basel). 2021;14(6):560.
   PubMedGoogle Scholar
• Bäckberg M, Pettersson Bergstrand M, Beck O, et al. Occurrence and time course of NPS benzodiazepines in Sweden - results from intoxication cases in the STRIDA project. Clin Toxicol (Phila). 2019;57(3):203–212.
   PubMed Web of Science ®Google Scholar
• Orsolini L, Corkery JM, Chiappini S, et al. ‘New/Designer Benzodiazepines’: an analysis of the literature and psychonauts’ Trip Reports. Curr Neuropharmacol. 2020;18(9):809–837.
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Shader RI. Benzodiazepines in clinical practice. New York: Raven Press; 1974.
   Google Scholar
• Greenblatt DJ, Shader RI. Benzodiazepines. N Engl J Med. 1974;291(19):1011–1015, 1239–1241.
   Web of Science ®Google Scholar
• Greenblatt DJ, Shader RI, Shader RI. Current status of benzodiazepines. N Engl J Med. 1983;309(6):354–358, 410–416.
   Web of Science ®Google Scholar
• Shader RI, Greenblatt DJ, Greenblatt DJ. Use of benzodiazepines in anxiety disorders. N Engl J Med. 1993;328(19):1398–1405.
   PubMed Web of Science ®Google Scholar
• Reves JG, Fragen RJ, Vinik HR, et al. Midazolam: pharmacology and uses. Anesthesiology. 1985;62(3):310–324.
   PubMed Web of Science ®Google Scholar
• Roehrs T, Roth T. Insomnia pharmacotherapy. Neurotherapeutics. 2012;9(4):728–738.
   PubMed Web of Science ®Google Scholar
• Shader RI, Greenblatt DJ. The use of benzodiazepines in clinical practice. Br J Clin Pharmacol. 1981;11(Suppl 1):5s–9s.
   PubMedGoogle Scholar
• Greenblatt DJ, Harmatz JS, Shader RI. Update on psychotropic drug prescribing in the United States: 2014–2015. J Clin Psychopharmacol. 2018;38(1):1–4.
   PubMed Web of Science ®Google Scholar
• Lukić V, Micić R, Arsić B, et al. Overview of the major classes of new psychoactive substances, psychoactive effects, analytical determination and conformational analysis of selected illegal drugs. Open Chem. 2021;19(1):60–106.
   Web of Science ®Google Scholar
• Bade R, Ghetia M, White JM, et al. Determination of prescribed and designer benzodiazepines and metabolites in influent wastewater. Anal Methods. 2020;12(28):3637–3644.
   PubMed Web of Science ®Google Scholar
• Garland JM, Hull JD, Bender CL, et al. Evidence of designer benzodiazepine use in routine healthcare urine drug specimens. J Addict Med. 2022;16(3):354–356.
   PubMed Web of Science ®Google Scholar
• DiTrana A, LaMaida N. New psychoactive substances consumption and their monitoring during Covid-19 pandemic. Clin Ter. 2021;172(4):271–272.
   PubMedGoogle Scholar
• Greenblatt DJ, Divoll M, Abernethy DR, et al., Benzodiazepine kinetics: implications for therapeutics and pharmacogeriatrics. Drug Metab Rev. 1983;14(2): 251–292.
   PubMed Web of Science ®Google Scholar
• Carpenter JE, Murray BP, Dunkley C, et al. Designer benzodiazepines: a report of exposures recorded in the National Poison Data System, 2014–2017. Clin Toxicol (Phila). 2019;57(4):282–286.
   PubMed Web of Science ®Google Scholar
• Essink S, Nugteren-van Lonkhuyzen JJ, van Riel AJHP, et al. Significant toxicity following an increase in poisonings with designer benzodiazepines in the Netherlands between 2010 and 2020. Drug Alcohol Depend. 2022 Feb 1;231:109244.
   PubMed Web of Science ®Google Scholar
• Drevin G, Briet M, Ferec S, et al. Toxicity of designer benzodiazepines: a case of etizolam and cocaine intoxication. Forensic Sci Int. 2022;336:111324.
   PubMed Web of Science ®Google Scholar
• O’Connell CW, Sadler CA, Tolia VM, et al. Overdose of etizolam: the abuse and rise of a benzodiazepine analog. Ann Emerg Med. 2015;65(4):465–466.
   PubMed Web of Science ®Google Scholar
• Shearer K, Bryce C, Parsons M, et al. Phenazepam: a review of medico-legal deaths in South Scotland between 2010 and 2014. Forensic Sci Int. 2015;254:197–204.
   PubMed Web of Science ®Google Scholar
• Darke S, Peacock A, Duflou J, et al. Characteristics of fatal ‘novel’ benzodiazepine toxicity in Australia. Forensic Sci Int. 2022;331:111140.
   PubMed Web of Science ®Google Scholar
• Simonsen KW, Kriikku P, Thelander G, et al. Fatal poisoning in drug addicts in the Nordic countries in 2017. Forensic Sci Int. 2020;313:110343.
   PubMed Web of Science ®Google Scholar
• Papsun DM, Krotulski AJ, Homan J, et al. Flualprazolam blood concentrations in 197 forensic investigation cases. J Anal Toxicol. 2021;45(3):226–232.
   PubMed Web of Science ®Google Scholar
• Norman C. A global review of prison drug smuggling routes and trends in the usage of drugs in prisons. WIREs Forensic Sci. 2022;4:e1473.
   Google Scholar
• Vaccaro G, Massariol A, Guirguis A, et al. NPS detection in prison: a systematic literature review of use, drug form, and analytical approaches. Drug Test Anal. 2022;14(8):1350–1367.
   PubMed Web of Science ®Google Scholar
• Heide G, Høiseth G, Middelkoop G, et al. Blood concentrations of designer benzodiazepines: relation to impairment and findings in forensic cases. J Anal Toxicol. 2020;44(8):905–914.
   PubMed Web of Science ®Google Scholar
• Perez Orts M, van Asten A, Kohler I. The evolution towards designer benzodiazepines in drug-facilitated sexual assault cases. J Anal Toxicol. 2022 Mar 16: bkac017. Doi: 10.1093/jat/bkac017.
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ. The pharmacovigilance syndrome. J Clin Psychopharmacol. 2015;35(4):361–363.
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Roth T. Zolpidem for insomnia. Exp Opin Pharmacother. 2012;13(6):879–893.
   PubMed Web of Science ®Google Scholar
• Cornett EM, Novitch MB, Brunk AJ, et al. New benzodiazepines for sedation. Best Pract Res Clin Anaesthesiol. 2018;32(2):149–164.
   PubMed Web of Science ®Google Scholar
• Sternbach LH. The benzodiazepine story. Prog Drug Res. 1978;22:229–266.
   PubMedGoogle Scholar
• Sternbach LH. The discovery of Librium. 1972. Agents Actions. 1994;43(3–4):82–85.
   PubMedGoogle Scholar
• Waters L, Manchester KR, Maskell PD, et al. The use of a quantitative structure-activity relationship (QSAR) model to predict GABA-A receptor binding of newly emerging benzodiazepines. Sci Justice. 2018;58(3):219–225.
   PubMed Web of Science ®Google Scholar
• Catalani V, Botha M, Corkery JM, et al. The Psychonauts’ Benzodiazepines; Quantitative Structure-Activity Relationship (QSAR) analysis and docking prediction of their biological activity. Pharmaceuticals (Basel). 2021;14(8):720.
   PubMedGoogle Scholar
• El Balkhi S, Monchaud C, Herault F, et al. Designer benzodiazepines’ pharmacological effects and potencies: how to find the information. J Psychopharmacol. 2020;34(9):1021–1029.
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Shader RI, Koch-Weser J. Flurazepam hydrochloride, a benzodiazepine hypnotic. Ann Intern Med. 1975;83(2):237–241.
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Shader RI, Koch-Weser J. Flurazepam hydrochloride. Clin Pharmacol Ther. 1975;17(1):1–14.
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Divoll M, Harmatz JS, et al. Kinetics and clinical effects of flurazepam in young and elderly noninsomniacs. Clin Pharmacol Ther. 1981;30(4):475–486.
   PubMed Web of Science ®Google Scholar
• Miller LG, Greenblatt DJ, Abernethy DR, et al. Kinetics, brain uptake, and receptor binding characteristics of flurazepam and its metabolites. Psychopharmacology (Berl). 1988;94(3):386–391.
   PubMed Web of Science ®Google Scholar
• Katselou M, Papoutsis I, Nikolaou P, et al. Metabolites replace the parent drug in the drug arena. The cases of fonazepam and nifoxipam. Forensic Toxicol. 2017;35(1):1–10.
   PubMed Web of Science ®Google Scholar
• Griffin CE, Kaye AM, Bueno FR, et al. Benzodiazepine pharmacology and central nervous system-mediated effects. Ochsner J. 2013;13(2):214–223.
   PubMedGoogle Scholar
• Peng L, Morford KL, Levander XA. Benzodiazepines and related sedatives. Med Clin North Am. 2022;106(1):113–129.
   PubMed Web of Science ®Google Scholar
• Łukasik-Głębocka M, Sommerfeld K, Teżyk A, et al. Flubromazolam – a new life-threatening designer benzodiazepine. Clin Toxicol (Phila). 2016;54(1):66–68.
   PubMed Web of Science ®Google Scholar
• DeCandia MP, DiSciascio G, Durbano F, et al. Effects of treatment with etizolam 0.5 mg Bid on cognitive performance: a 3-week, multicenter, randomized, double-blind, placebo-controlled, two-treatment, three-period, noninferiority crossover study in patients with anxiety disorder. Clin Ther. 2009;31(12):2851–2859.
   PubMed Web of Science ®Google Scholar
• Catalani V, Botha M, Corkery JM, et al. Designer benzodiazepines’ activity on opioid receptors: a docking study. Curr Pharm Des. 2022;28(32):2639–2652.
   PubMed Web of Science ®Google Scholar
• Moosmann B, Bisel P, Auwärter V. Characterization of the designer benzodiazepine diclazepam and preliminary data on its metabolism and pharmacokinetics. Drug Test Anal. 2014;6(7–8):757–763.
   PubMed Web of Science ®Google Scholar
• Moosmann B, Huppertz LM, Hutter M, et al. Detection and identification of the designer benzodiazepine flubromazepam and preliminary data on its metabolism and pharmacokinetics. J Mass Spectrom. 2013;48(11):1150–1159.
   PubMed Web of Science ®Google Scholar
• Moosmann B, Bisel P, Franz F, et al. Characterization and in vitro phase I microsomal metabolism of designer benzodiazepines - an update comprising adinazolam, cloniprazepam, fonazepam, 3-hydroxyphenazepam, metizolam and nitrazolam. J Mass Spectrom. 2016;51(11):1080–1089.
   PubMed Web of Science ®Google Scholar
• Ékonomov AL, Zherdev VP. Method of quantitative gas-chromatographic determination of phenazepam and its metabolite 3-hydroxyphenazepam in plasma. Pharm Chem J. 1980;14(8):579–582.
   Google Scholar
• Venkatakrishnan K, von Moltke LL, Duan SX, et al. Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man. J Pharm Pharmacol. 2011;50(3):265–274.
   Google Scholar
• Venkatakrishnan K, Culm KE, Ehrenberg BL, et al. Kinetics and dynamics of intravenous adinazolam, N-desmethyl adinazolam, and alprazolam in healthy volunteers. J Clin Pharmacol. 2005;45(5):529–537.
   PubMed Web of Science ®Google Scholar
• Wagmann L, Manier SK, Felske C, et al. Flubromazolam-derived designer benzodiazepines: toxicokinetics and analytical toxicology of clobromazolam and bromazolam. J Anal Toxicol. 2021;45(9):1014–1027.
   PubMed Web of Science ®Google Scholar
• Meyer MR, Bergstrand MP, Helander A, et al. Identification of main human urinary metabolites of the designer nitrobenzodiazepines clonazolam, meclonazepam, and nifoxipam by nano-liquid chromatography-high-resolution mass spectrometry for drug testing purposes. Anal Bioanal Chem. 2016;408(13):3571–3591.
   PubMed Web of Science ®Google Scholar
• Huppertz LM, Bisel P, Westphal F, et al. Characterization of the four designer benzodiazepines clonazolam, deschloroetizolam, flubromazolam, and meclonazepam, and identification of their in vitro metabolites. Forensic Toxicol. 2015;33(2):388–395.
   Web of Science ®Google Scholar
• Nakamae T, Shinozuka T, Sasaki C, et al. Case report: etizolam and its major metabolites in two unnatural death cases. Forensic Sci Int. 2008;182(1–3):e1–6.
   PubMedGoogle Scholar
• El Balkhi S, Chaslot M, Picard N, et al. Characterization and identification of eight designer benzodiazepine metabolites by incubation with human liver microsomes and analysis by a triple quadrupole mass spectrometer. Int J Legal Med. 2017;131(4):979–988.
   PubMed Web of Science ®Google Scholar
• Wohlfarth A, Vikingsson S, Roman M, et al. Looking at flubromazolam metabolism from four different angles: metabolite profiling in human liver microsomes, human hepatocytes, mice and authentic human urine samples with liquid chromatography high-resolution mass spectrometry. Forensic Sci Int. 2017;274:55–63.
   PubMed Web of Science ®Google Scholar
• Moosmann B, Bisel P, Westphal F, et al. Characterization and in vitro phase 1 microsomal metabolism of designer benzodiazepines: an update comprising flunitrazolam, norflurazepam, and 4’-chlorodiazepam (Ro5-4864). Drug Test Anal. 2019;11(3):541–549.
   PubMed Web of Science ®Google Scholar
• Pettersson Bergstrand M, Meyer MR, Beck O, et al. Human urinary metabolic patterns of the designer benzodiazepines flubromazolam and pyrazolam studied by liquid chromatography-high resolution mass spectrometry. Drug Test Anal. 2018;10(3):496–506.
   PubMed Web of Science ®Google Scholar
• Pettersson Bergstrand M, Richter LHJ, Maurer HH, et al. In vitro glucuronidation of designer benzodiazepines by human UDP-glucuronyltransferases. Drug Test Anal. 2019;11(1):45–50.
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ. Clinical pharmacokinetics of oxazepam and lorazepam. Clin Pharmacokinet. 1981;6(2):89–105.
   PubMed Web of Science ®Google Scholar
• Locniskar A, Greenblatt DJ. Oxidative versus conjugative biotransformation of temazepam. Biopharm Drug Dispos. 1990;11(6):499–506.
   PubMed Web of Science ®Google Scholar
• Peng L, Lawrence D, Levander XA. Challenges of diagnosing and managing designer benzodiazepine dependence and withdrawal: a case report. J Addict Med. 2022;16(2):249–251.
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Allen MD, Noel BJ, et al. Acute overdosage with benzodiazepine derivatives. Clin Pharmacol Ther. 1977;21(4):497–514.
   PubMed Web of Science ®Google Scholar
• Allen MD, Greenblatt DJ, LaCasse Y, et al. Pharmacokinetic study of lorazepam overdosage. Am J Psychiatry. 1980;137(11):1414–1415.
   PubMed Web of Science ®Google Scholar
• Divoll M, Greenblatt DJ, Lacasse Y, et al. Benzodiazepine overdosage: plasma concentrations and clinical outcome. Psychopharmacology (Berl). 1981;73(4):381–383.
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Woo E, Allen MD, et al. Rapid recovery from massive diazepam overdose. JAMA. 1978;240(17):1872–1874.
   PubMed Web of Science ®Google Scholar
• Nielsen S, McAuley A. Etizolam: a rapid review on pharmacology, non-medical use and harms. Drug Alcohol Rev. 2020;39(4):330–336.
   PubMed Web of Science ®Google Scholar